PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of oncotargetLink to Publisher's site
 
Oncotarget. 2017 August 29; 8(35): 58934–58947.
Published online 2017 July 24. doi:  10.18632/oncotarget.19515
PMCID: PMC5601704

Use of confocal laser endomicroscopy with a fluorescently labeled fatty acid to diagnose colorectal neoplasms

Abstract

Endoscopic treatment for early colorectal cancer closely correlates with patient prognosis. However, endoscopic differentiation between carcinomas and non-neoplastic lesions remains difficult. Here, we topically stained colorectal neoplasms with a fatty acid analogue (BODIPY-FA) and quantified the fluorescent signals using confocal laser endomicroscopy (CLE) and fluorescence microscopy. We also analyzed protein expression in colorectal cancer tissues. We found that expression of fatty acid synthase was elevated, while the expression of fatty acid transporters was reduced in colorectal cancer. In colorectal cancer mouse models and patients, the BODIPY-FA signals were higher in normal epithelia than in carcinomas or colonic intraepithelial neoplasias. BODIPY-FA staining revealed both the arrangement of intestinal glands and the intracellular structures under CLE screening. In a double-blind trial, CLE images stained with BODIPY-FA exhibited greater consistency (κ = 0.68) and overall validity (74.65%) than those stained using intravenous fluorescein sodium (κ = 0.43, 55.88%) when the results were compared with histological diagnoses. These findings suggest that topical use of BODIPY-FA with CLE is a promising imaging approach for early colorectal neoplasm screening.

Keywords: fatty acid metabolism, colorectal neoplasm, confocal laser endomicroscopy, fluorescent agents, de novo FA synthesis

INTRODUCTION

Cancer cell metabolism differs significantly from normal cell metabolism. Most proliferating cancer cells take up more glucose and produce more lactate via the glycolytic pathway than normal cells, even when oxygen is abundant [15]. This so-called ‘Warburg effect’ has been intensively studied and generally applied in clinical positron emission tomography–computed tomography [6, 7]. In addition, endogenous fatty acid (FA) synthesis (also called de novo FA synthesis) is specifically enhanced in cancer cells, irrespective of the exogenous lipid supply [811]. This process is another important metabolic hallmark of cancer [1214]. De novo FA synthesis generates long-chain fatty acids (LCFAs) from acetyl-CoA, and accounts for the synthesis of almost all esterified FAs and more than 93% of triglycerides to meet the biosynthetic demands of tumors [15]. However, the practical applications of this phenomenon have not been fully explored.

As colorectal cancer (CRC) is the third-most-common cancer in males and the second-most-common cancer in females worldwide [16], early CRC detection is crucial for improving the quality of life and the cure rate for patients. Colonoscopy has been regarded as the gold standard for screening people at high risk for CRC. Multiple novel endoscopic technologies have recently been investigated, including narrow-band imaging (NBI), Fujinon intelligent chromoendoscopy (FICE), magnifying chromoendoscopy (MCE) and confocal laser endomicroscopy (CLE) [17, 18]. CLE integrates experimental confocal microscopy with conventional optical endoscopy, magnifying regions of interest (ROIs) 1000-fold at the cellular and sub-cellular levels and allowing real-time in vivo histology in the clinical diagnosis of colorectal neoplasms [19, 20]. Although fluorescently labeled antibodies and peptides have been tested with CLE [2124], labeled FAs have never been used in trials to evaluate colorectal neoplasms specifically on a metabolic level.

The fluorescently labeled FA analogue BODIPY-FA (4,4-difluoro-5-methyl-4-bora-3a,4a diaza-s-indacene-3-dodecanoic acid) is activated by argon-ion laser excitation at 488 nm, and has generally been applied for experimental research in lipid trafficking [25]. In this study, we found that BODIPY-FA was a promising biomarker for tumor imaging, due to the reprogramming of FA metabolism in CRC cells. Furthermore, upon its absorption, BODIPY-FA was enriched in the cytoplasm, and created contrast that allowed negative nuclear visualization. Thus, BODIPY-FA provided histological imaging similar to hematoxylin and eosin (H&E) staining, making it superior to other newly developed contrast agents.

RESULTS

FA metabolism differed between normal colorectal and CRC samples

Analysis of data from the Clinical Proteomic Tumor Analysis Consortium indicated that most enzymes involved in de novo FA synthesis, including FASN, acetyl-CoA carboxylase (ACC) and ATP citrate lyase (ACLY), were expressed at significantly higher levels in CRC tissues than in normal colorectal tissues. In addition, the acetyl-CoA synthetase complex (ACSc) and carnitine palmitoyl transferase 2 (CPT2) were downregulated in CRC tissues, suggesting that FA oxidation is impaired in colonic carcinoma (Figure (Figure1A1A and Supplementary Figure 1, detailed in Supplementary Table 4). More importantly, concomitant with the enhancement of endogenous FA synthesis, the expression of membranal transporters of LCFAs, such as plasma membrane FABP (FABPpm) and FABP1, decreased sharply in CRC (Figure (Figure1A1A and Supplementary Figure 1). Western blotting revealed that FASN protein expression was elevated in CRC tissues, while real-time PCR and Western blotting indicated that FABP1, CD36 and Caveolin-1 mRNA and protein levels were reduced in CRC (Figure (Figure1B,1B, ,1C),1C), potentially due to the reduced availability of exogenous lipids for the tumor.

Figure 1
Elevated de novo fatty acid synthesis combined with reduced fatty acid oxidation in human CRC

LCFA transport begins with the uptake of circulating non-esterified FAs (derived from triglycerides) by membranal transporters. Previously, FA uptake studies relied on radiolabeled lipids, and thus lacked real-time dynamic monitoring and were costly [32]. BODIPY-FA is a fluorescently labeled FA consisting of a 12-carbon saturated FA chain connected to the fluorophore BODIPY. BODIPY-FA biologically resembles an 18-carbon FA, and is reported to be a suitable alternative to radiolabeled FAs [33]. Stearic acid (C18:0) is a dominant member of the non-esterified LCFA family, and is the main source of FA oxidation for cellular energy after its uptake by lipid transporters [34]. Through FACS analysis, we found that stearic acid could effectively compete with the BODIPY-FA signal in SW480 cells (Figure (Figure1D),1D), confirming that BODIPY-FA is a C18:0 analogue. Thus, BODIPY-FA could be a tool for monitoring lipid transport, and could reflect the natural uptake of circulating non-esterified LCFAs in vivo.

BODIPY-FA uptake was reduced in human CRC cells

Based on the downregulation of FA transporters in human CRC tissues, we hypothesized that exogenous FA uptake is limited in cancer. To verify this hypothesis, we used BODIPY-FA to examine the differences in FA metabolism between CRC cells and normal colonic cells in vitro. FACS analysis demonstrated that BODIPY-FA accumulated in adherent cells within 15 minutes, and that the fluorescent signal was greater in a normal colonic cell line (FHC) than in CRC cell lines (SW480, HCT116, and LOVO) (P < 0.0001, Figure Figure2A).2A). FACS analysis of three pairs of fresh cancerous and matched normal colonic tissues revealed the same trend in the BODIPY-FA signal, and the absorption of normal primary colonic epithelial cells plateaued within five minutes (Figure (Figure2B2B).

Figure 2
BODIPY-FA absorption by CRC cell lines and normal FHC cells

Next, we determined the ability of confocal laser microscopy to locate and discriminate BODIPY-FA staining. A stronger cellular signal was observed for FHC cells than for CRC cells (SW480, LOVO) (P < 0.0001, Figure Figure2C).2C). In addition, the specific BODIPY-FA signal was cytoplasmic and perinuclear (Figure 2D–2F). These data indicated that LCFA uptake was reduced in CRC cells, and that limited exogenous FA usage may be an intrinsic signature of tumor lipid metabolism.

Fluorescence microscopy revealed reduced BODIPY-FA uptake by colonic neoplasms in mouse models in vivo

Next, we topically administered fluorescent agents to both AOM/DSS-induced and xenograft models, and analyzed the cytoplasmic fluorescence intensity under fluorescence microscopy. When we analyzed the colitis-related carcinomas produced in the AOM/DSS model, we found a stepwise decrease in the BODIPY-FA signal, which was strong in non-neoplastic samples, lower in CIN samples, and even lower in adenocarcinoma samples (Figure (Figure3A,3A, ,3B,3B, Supplementary Figure 3A). In addition, the BODIPY-FA signals from adenocarcinoma and CIN samples were approximately 39.3% (P < 0.0001) and 17.7% (P = 0.0117) lower, respectively, than in normal epithelia (Figure (Figure3D).3D). The BODIPY-FA signals from orthotopically implanted tumors of xenograft mice were approximately 10.2% lower than those of paired normal mucosae (P = 0.0017, Figure Figure3C,3C, ,3E3E).

Figure 3
Fluorescence microscopy imaging after topical application of BODIPY-FA to the mucosae of mouse models, and the corresponding H&E images

Based on this difference, we used the deoxyglucose analogue 2-NBDG as a control, in which 2-deoxyglucose is linked to the fluorophore N-(7-nitrobenz-2-oxa-1,3-diaxol-4-yl)amino (NBD). The 2-NBDG signals were approximately 20% greater in neoplastic mucosae than in normal mucosae from AOM/DSS-induced mice (P = 0.0119, Supplementary Figure 2A, 2C). The 2-NBDG absorption was also higher in inflamed tissues than in normal mucosae (P = 0.0209, Supplementary Figure 3B). However, there were no differences between the normal tissues and the tumors in the xenograft model after 2-NBDG staining (Supplementary Figure 2B). All fluorescent agent signals were greater than the background autofluorescence.

CLE revealed reduced BODIPY-FA uptake by colonic neoplasms in mouse models in vivo

Because of the BODIPY-FA signal differences observed with fluorescence microscopy, we then performed CLE with topically applied fluorescent agents to explore the uptake differences in vivo. In AOM/DSS-induced mice, the BODIPY-FA signals declined progressively from inflamed to normal to CIN to adenocarcinoma tissues (Figure (Figure4A,4A, ,4B4B and Figure Figure5A).5A). The mean greyscale values of the normal mucosae were 2.5 and 1.7 times greater than those of adenocarcinomas and CIN, respectively (Figure (Figure4C).4C). In parallel, the BODIPY-FA signal was 2.1-fold higher in normal tissues than in colonic orthotopic tumors (Figure (Figure5C,5C, ,5D).5D). For APC-min mice, the BOPIDY-C12 signal was significantly higher in normal mucosae than in adenomas, according to CLE (P < 0.0001) and fluorescence microscopy (P = 0.0001) (Figure 4D–4F). Furthermore, changes in cellular structures, such as the disorganized cellular arrangement and cellular atypia in the neoplastic lesions, were more well-defined under CLE with BODIPY-FA staining than with other contrast agents.

Figure 4
CLE images following topical application BODIPY-FA to the mucosae of mouse models, and the corresponding H&E images
Figure 5
CLE images following topical application of fluorescent agents to the mucosae of mouse models, and corresponding H&E images

In contrast, CLE following topical administration of 2-NBDG did not facilitate clear outlining of the glands, let alone cytoplasmic imaging, and no fluorescent difference between neoplastic and non-neoplastic tissues was observed in the mouse models (Figure (Figure5B,5B, ,5E).5E). For acriflavine staining, the nuclei within the ROIs were all displayed (Supplementary Figure 4A, 4B). No background autofluorescence was observed in normal or malignant tissues.

CLE revealed reduced BODIPY-FA uptake in colonic neoplasms in patients

We further used BODIPY-FA with CLE to explore lipid uptake in human samples. The mean greyscale values of all distinguishable confocal images (149 non-neoplasm images, 103 low-grade IN images, 132 high-grade IN images, and 124 adenocarcinoma images) of patients were analyzed under the same excitation brightness control. Images with obvious impurities on the tissue surface were eliminated from the assessment. The BODIPY-FA signals of non-neoplastic sites were almost 1.6-, 2- and 2.2-fold higher than those of low-grade IN, high-grade IN and cancerous sites, respectively, but the signals of high-grade IN and adenocarcinoma sites did not differ significantly from one another (Figure (Figure6G6G).

Figure 6
CLE imaging of patient samples and the corresponding H&E images

Staining characteristics of BODIPY-FA and classification of colorectal neoplasms by CLE

We also analyzed the characteristics of BODIPY-FA staining with CLE. At normal sites, black nuclei on the basal side and bright cytoplasmic staining facilitated the visualization of regularly arranged crypts, which were surrounded by epithelial cells and goblet cells. With regard to hyperplastic polyps, focal aggregations of regularly shaped crypts or typical star-shaped luminal crypt openings were visible, and the number of goblet cells was normal or slightly reduced (Figure (Figure6A,6A, ,6B).6B). BODIPY-FA staining on adenocarcinomas was greatly altered, revealing many atypical cells with large and irregularly shaped nuclei (Figure (Figure6E,6E, ,6F6F).

Next, we evaluated the potential use of BODIPY-FA with CLE for the early diagnosis of neoplasms. In low-grade IN, BODIPY-FA-stained lesions exhibited slightly atypical or elongated glands with a single layer of nuclei on the basal side. Moreover, the nucleus-to-cytoplasm ratio was almost normal, in spite of the slightly reduced number of goblet cells. Strikingly, for high-grade IN, ROIs displayed lateral fusion of destroyed crypts, extremely elongated and branch-like crypts, and an increased nucleus-to-cytoplasm ratio. In addition, goblet cells were either reduced in number or completely absent (Figure (Figure6C,6C, ,6D6D).

Comparison between CLE diagnosis and clinical histological findings

Finally, we performed a clinical comparison of CLE diagnosis and histological assessments. The inter-observer agreement was greater for BODIPY-FA staining (κ = 0.72, P < 0.001) than for fluorescein sodium (κ = 0.61, P < 0.001). The overall validity of CLE versus H&E diagnosis was 74.65% with BODIPY-FA and 55.88% with fluorescein sodium. In addition, there was good diagnostic consistency (κ = 0.68, P < 0.001) between BODIPY-FA images and H&E diagnosis. However, although the diagnostic difference was slight (chi-square = 1.10, P = 0.9540), the consistency with the histological diagnosis was worse for fluorescein sodium than for BODIPY-FA (κ = 0.43, P < 0.001). These results are detailed in Supplementary Tables 2 and 3, indicating that CLE with BODIPY-FA staining had greater consistency and overall validity than CLE with intravenous fluorescein sodium.

DISCUSSION

Endoscopic treatment for CRC at the early stage can effectively improve the cure rate for patients. In this study, we found that lipid metabolism was aberrant in CRC, and that the uptake of the fluorescently labeled FA BODIPY-FA was reduced in CRC tissues from both mouse models and human patients. BODIPY-FA staining under CLE effectively differentiated non-neoplastic tissues, colonic IN and carcinomas, as it created a strong fluorescent contrast and allowed clear visualization of cellular structures. BODIPY-FA with CLE enabled real-time cellular and sub-cellular imaging of ROIs, and defined a much more accurate boundary between neoplasm and non-neoplasm than existing methods; thus, this technique may facilitate early CRC identification for further clinical treatments.

Multiple novel endoscopic technologies have been investigated for early CRC identification, such as NBI, FICE, MCE and CLE. NBI can differentiate neoplasms from non-neoplasms according to surface microvessel changes, but poorly detects depressed-type lesions [35]. MCE with crystal violet staining has a diagnostic accuracy of 85–88% based on surface pit pattern identification [36]. However, disappointing misdiagnoses and missed diagnoses still occur, due to the variety of superficial lesions and the limited role of forceps biopsy; in fact, the disagreement between histopathology and resected biopsy tissues has been reported to be approximately 40% [37]. In contrast, with its 1000× magnifying visualization, CLE has been shown to have 93.9% sensitivity and 95.9% specificity for colonic adenoma detection [38].

CLE diagnosis has relied exclusively on fluorescent staining agents such as fluorescein sodium and acriflavine thus far. BODIPY-FA is a C18:0 analogue, and can distinctly highlight the structure of the cell nucleus in mouse models when it is applied topically. Although systemic agents such as fluorescein sodium have the advantage of reduced immunogenicity, their localization in blood vessels prevents them from displaying the morphology of the intracellular architecture. Topical agents have been used preferentially in clinical settings [39, 40], since they allow real-time imaging of ROIs and can be applied easily during CLE. In our trial, due to its low molecular weight and hydrophobic features, BODIPY-FA rapidly entered the cytoplasm (within five minutes) and accumulated stably in the cytoplasm. Given its rapid and relatively stable imaging of ROIs, CLE screening with BODIPY-FA is more convenient and efficient than CLE with fluorescein sodium.

In addition to rapid cellular imaging, in our study, BODIPY-FA with CLE effectively visualized enlarged glands with different arrangements and, more importantly, distinguished between normal and aberrant nucleus-to-cytoplasm ratios in both mouse models and human tissues. In contrast, 2-NBDG failed to visualize nuclei or glands under CLE. Furthermore, the overall prediction consistency and accuracy were much greater for CLE with BODIPY-FA than with fluorescein sodium. Thus, malignant lesions displayed weak BODIPY-FA signals, accompanied by increased nucleus-to-cytoplasm ratios under CLE. In addition, as the elevated BODIPY-FA signals in inflamed sites were parallel to those in normal mucosae, BODIPY-FA imaging with CLE also facilitated the detection of colitis-associated carcinoma, thus assisting in the diagnosis of endoscopic depressed-type lesions. Overall, BODIPY-FA staining under CLE exploited differences in lipid metabolism and enhanced cellular visualization, thereby improving the diagnostic efficiency of CLE screening during CRC identification.

De novo FA synthesis is a common metabolic characteristic of cancer, and has been studied in various human cancers, including breast, colorectal, lung, prostate and liver cancer [41, 42]. This process is controlled by rate-limiting enzymes such as FASN and ACC, and generates FAs de novo from acetyl-CoA. Inhibitors of FASN (C75 or TVB-3166) or ACC (ND-646) have been shown to effectively suppress the growth and viability of cancer cells, demonstrating the importance of endogenous FA synthesis in oncology [43, 44]. Strikingly, exogenous FAs, in addition to being the main source of cellular energy, generally compete with de novo FA synthesis [45, 46]. In a previous study, growing cells in lipid-depleted medium clearly enhanced the effects of ND-646 by placing a heavier burden on endogenous FA synthesis [44]. On the other hand, the addition of palmitate fully restored cancer cell viability after the inhibition of FASN [43]. In our study, we found that FASN expression was increased in human CRC, while the expression of membranal transporters of LCFAs such as FABP1, CD36 and Caveolin-1 was reduced. The reduced expression of lipid transporters may further impair extracellular lipid uptake in CRC tissues relative to normal colonic mucosae. Further BODIPY-FA detection in vitro and in vivo also verified these findings. Thus, we propose that limited exogenous lipid usage directly manifests itself through the downregulation of LCFA transporters, and could be a response to increased de novo FA synthesis in CRC tissues. Further molecular research could focus on this interesting subject.

In summary, abnormal lipid metabolism in cancer cells caused distinct uptake patterns of the fluorescently labeled FA BODIPY-FA in non-neoplastic mucosae and neoplastic tissues, providing a novel approach for early CRC detection. This method specifically identified malignant sites with “dark areas” and allowed well-defined intracellular imaging under CLE, similar to “real-time histochemistry,” which enhanced the detection of suspicious lesions and enabled relatively reliable diagnoses. This method was also beneficial for the detection of inflammatory bowel disease-associated carcinoma, and could be a reliable screening tool for at-risk patients. We speculate that reduced exogenous FA uptake may be an inherent neoplastic characteristic that is representative of most other tumors. This research will open a new door to tracing pre-neoplastic or neoplastic lesions in scientific research and clinical practice.

MATERIALS AND METHODS

Cell culture and fluorescence-activated cell sorting (FACS)-based BODIPY-FA uptake assays

All cells were obtained from the American Type Culture Collection (Maryland, USA). Different CRC cell lines were cultured in Dulbecco's Modified Eagle Medium (10% fetal calf serum, 1% glutamine, 1% streptomycin /penicillin) at 37°C and 5% CO2. When cells reached 60–80% confluency, they were plated in 12-well plates covered with aluminum foil at a density of 500,000 cells/well and incubated overnight for adherence. BODIPY-FA (D3823, Invitrogen, Carlsbad, CA, USA) was dissolved in dimethyl sulfoxide as a stock solution [25], and the working solution was diluted with 1× phosphate-buffered saline (PBS) and 0.1% FA-free bovine serum albumin. Different cell lines were cultivated in 2 μM BODIPY-FA for 1–15 minutes. For fluorescent competition with stearic acid, SW480 cells were cultivated in various concentrations of a BODIPY-FA-stearic acid mixture for 15 minutes. Then, the cells were rinsed and harvested immediately for FACS analysis.

We also isolated primary colonic epithelial cells from cancerous and matched normal tissue samples, as described previously [26], after obtaining informed consent from the patients. Details on the patients are given in Supplementary Table 1.3.

For cellular staining with BODIPY-FA, FHC and CRC cell lines were cultured in confocal dishes and incubated with a 2-μM BODIPY-FA mix for 15 minutes. Cells were then fixed with 4% paraformaldehyde for 30 minutes, and the nuclei were counterstained with 4′,6-diamidino-2-phenylindole (DAPI; 4083, Cell Signaling Technology, Boston, MA, USA). Following fixation, cells were washed three times with pre-chilled PBS. Images were acquired with an FV1000 confocal laser scanning microscope (CLSM).

Animal model construction

Three different mouse models of CRC were studied. The experiments were approved by the Animal Ethics Committee of Southern Medical University (L2015006) and conducted in accordance with the animal experimentation guidelines of the Chinese Ministry of Health. For the generation of the chemically induced mouse model, six- to eight-week-old male Balb/c mice were intraperitoneally injected with 10 mg/kg body weight azoxymethane (AOM; A5486, Sigma-Aldrich, Saint Louis, MO, USA). One week later, 2.5% dextran sulfate sodium (DSS; MW 40000–50000 Da, MP, Santa Ana, California, USA) was dissolved in distilled water and administered for seven days, followed by 14 days of normal drinking water [27]. This cycle was repeated three times, and when the last DSS cycle ended, the mice were prepared for in vivo staining. Our run-in phase experiments demonstrated that the neoplastic regions always occurred near the rectum, with increased thickness and stiffness of the bowel wall macroscopically; these observations guided the topical application of the fluorescent agents. We successfully acquired 32 AOM/DSS-induced neoplastic mice; 14 were used for the first fluorescence microscopy imaging study (six for BODIPY-FA; six for 2-Deoxy-2-[(7-nitro-2,1,3-benzoxadiazol-4-yl)amino]-D-glucose (2-NBDG); and two for acriflavine hydrochloride), and 18 were used for in vivo CLE imaging (eight for BODIPY-FA; seven for 2-NBDG; and three for acriflavine hydrochloride).

For the xenograft model, 106 human LOVO CRC cells were orthotopically implanted through a laparotomy into the colonic serosa layer of Balb/c null mice (Medical Experimental Animal Centre of Guangdong Province, China) under stringent aseptic conditions. Subsequently, the abdominal cavity was closed with a commonly used disinfectant. Three to four weeks after the implantation, the mice received a second laparotomy for the next step. In total, 16 xenograft mice were successfully acquired, including eight for fluorescence microscopy imaging and eight for in vivo CLE imaging (four for BODIPY-FA staining and four for 2-NBDG staining).

APC-min mice (purchased from the Animal Model Research Centre of Nanjing University, China) are a widely accepted model of intestinal tumorigenesis. Six APC-min mice (four to six months old) received follow-up BODIPY-FA imaging.

Staining in the mouse models

Prior to the application of fluorescent agents, AOM/DSS-induced mice, xenograft mice and APC-min mice were fasted for 12 h. Anesthesia was administered with 0.01 g/mL pentobarbital, given as 6–7 μL/g body weight. For in vivo neoplastic staining, a 200 μM BODIPY-FA mix, 500 μM 2-NBDG (N13195, Invitrogen) and 0.05% acriflavine (A8251, Sigma-Aldrich) were prepared, and the colons and/or small intestines of the mice were isolated through laparotomy after a 2–3-cm long segment of the tract was created with two vascular hemoclips. Then, 100 μL of the fluorescent agent was injected directly into the lumen. After five minutes of staining, the stained areas were exposed, and the unbound BODIPY-FA was rinsed off three times with PBS.

Patients and tissue specimens

The sporadic colorectal neoplasm patients came from the Departments of Gastroenterology and General Surgery, Nanfang Hospital, Guangzhou, China. These patients were selected based on the following factors: (1) complete clinical follow-up data were available, and (2) the patients had not eaten large amounts of high-fat food or been taking lipid medicine. The Institutional Research Medical Ethics Committee of Nanfang Hospital granted approval for the present study (NFEC-2015-083). Informed written consent was obtained from patients before examination.

RT-PCR

Total RNA was extracted with TRIzol (Takara) from paired normal and cancerous tissues from CRC patients, and cDNA was synthesized with TAKARA reverse transcriptase (037A, TAKARA, China) with oligo-dT primers. The cDNA and SYBR Green Premix ExTaq were used for subsequent real-time PCR amplification on an LC480 System. The primer sequences are listed in Supplementary Table 5.

Western blotting

The protein levels of fatty acid synthase (FASN), fatty acid binding protein 1 (FABP1), Caveolin-1 and CD36 in the paired human CRC samples were examined by Western blotting. Antibodies for FASN, FABP1, Caveolin-1, CD36 and GAPDH were purchased from Cell Signaling Technology. Protein blots were incubated with the indicated primary antibodies and then with the appropriate secondary antibodies, and detection was performed with enhanced chemiluminescence according to the manufacturer's instructions.

Histochemistry

Active specimens from each region of the mouse models were immediately embedded with Optimum Cutting Temperature compound in liquid nitrogen for cryosectioning after the staining procedure. After being counterstained with DAPI, the cryosections were observed with fluorescence microscopy. The other cryosections were stained with H&E. Finally, the fluorescence images were matched with their corresponding H&E images. The mean fluorescence intensity was calculated for statistical analysis. H&E images were analyzed independently by B.N. and H.Z.

CLE system

CLE (EC3830FK, Pentax, Japan) integrates experimental confocal microscopy with conventional optical endoscopy, delivering an excitation wavelength of 488 nm and an emission wavelength of 505–585 nm. A confocal probe was placed onto the mucosal layer for scanning, and optical sections of 475 × 475 μm were obtained. The axial resolution was 7 μm, and the lateral resolution was 0.7 μm (1024 × 1024 pixels). The imaging depth (z-axis) varied from 0–250 μm below the surface layer in 4-μm increments. Confocal images were obtained at a fixed laser power of 500 μW and standardized brightness.

Staining of human tissues and CLE imaging

Patients were randomly divided into the fluorescein sodium group and the BODIPY-FA group (detailed in Supplementary Tables 1.1 and 1.2). Fluorescein sodium (5–10 mL of a 10% solution, Baiyunshan Mingxing Pharmaceutical Co.) was administered intravenously according to a published protocol [28]. The 200-μM BODIPY-FA mix was applied topically for five minutes and then rinsed off with PBS.

For CLE imaging, when the confocal window is fully placed on the surface mucosa (for both in vivo mouse models and human tissues) and the imaging plane depth is real-time adjusted during ongoing screening, the observation time for each site should be shorter than 20 s. CLE was performed by two experienced endomicroscopists (W.G. or T.L.).

Confocal pattern classification

For the assessment of confocal images, clear images of each site were selected and evaluated according to previous classifications [20, 29] by two different endoscopy doctors, with three main histopathologic characteristics taken into consideration. Disagreements between the two observers were resolved by discussion, and the final diagnosis was agreed upon by both physicians. One characteristic was crypt morphology, which allowed the images to be classified into normal mucosa, hyperplastic locations and neoplasia (intraepithelial neoplasia [IN] and adenocarcinoma). The second characteristic was nuclear visualization, which permitted differentiation among low-grade IN, high-grade IN and adenocarcinoma. The last characteristic was the apparent darkness of the neoplasm compared with normal areas of the same patient under the same conditions. A detailed classification of the BODIPY-FA images from our patient samples is shown in Table Table1.1. The H&E biopsy images were judged independently by two experts and graded according to the modified Vienna classification [30]. In addition, clear images with intravenous fluorescein sodium were selected and judged in strict accordance with previous classification criteria [20].

Table 1
Confocal laser endomicroscopy criteria for BODIPY-FA imaging for colorectal pathology

Statistical analysis and evaluation

Mean greyscale values and mean fluorescence intensities were analyzed with Image J (NIH, Bethesda, MD, USA). CLE images were analyzed based on the following standards: (1) the observation time was less than 20 s per site and (2) recognizable cellular structures were visible. ROIs of 100 × 100 μm from three different regions per image were selected for the calculation of the mean greyscale value and mean fluorescence intensity. Data were analyzed with the statistical software package SPSS v13.0 (SPSS Inc., Chicago, IL, USA). Significance was determined with Student's t-test, one-way or two-way ANOVA, or a nonparametric test, as appropriate. The Kolmogorov-Smirnov test was performed to compare relative protein expression in the primary data of 95 tumor samples from the Clinical Proteomic Tumor Analysis Consortium. All P values were generated with two-sided tests, and P < 0.05 was defined as significant.

Double-blind trial for CLE diagnosis

Seventy-one target locations from 17 patients, including up to 508 confocal images (mean: 7 per site, range: 5–20) with BODIPY-FA, and an additional 68 target locations from 45 patients, including up to 950 images (mean: 14 per site, range: 7–65) with fluorescein sodium, were randomly coded and separately sent to two expert endomicroscopists (FC.Z. and F.H.D.) who were blinded to the macroscopic appearance and H&E diagnosis. All data were analyzed with SAS 9.4 software. The overall validity was calculated to compare the predictive ability of confocal endomicroscopy with that of the gold-standard H&E diagnosis. The Bhapkar test and Kappa coefficient were used to evaluate the diagnostic difference and consistency, respectively, between H&E staining and CLE with either BODIPY-FA or fluorescein sodium [31]. The Kappa coefficient was also used to evaluate the inter-observer agreement of the CLE diagnoses with BODIPY-FA or fluorescein sodium staining.

Writing assistance

We acknowledge Dr. Zhifei Shao at Stanford University for his help in editing this manuscript.

SUPPLEMENTARY MATERIALS FIGURES AND TABLES

Footnotes

Contributed by

Authors’ contributions

FH.D., Y.F.: draft of the manuscript, data acquisition and analysis. W.G., T.L.: endoscopic operation. FC.Z., FH.D.: judgment of the confocal images. WL.Z., T.W.: proteomic analysis. J.W.: ethical application. ZY.S., XJ.Z.: material and technological support. B.N., H.Z.: judgment of the histopathology images. B.N.: study concept and design, acquisition of funding and study supervision.

CONFLICTS OF INTEREST

The authors have applied for an international patent about this study.

FUNDING

This study was sponsored by the Returned Scientific Research Foundation of the Ministry of Education and the National Natural and Science Foundation of China [81471080] to B.N. This work was also supported by the National Basic Research Program “973” of China [2014CBA0200203 to Bo Jiang1.] The 95 samples of protein data in this study were generated from the Clinical Proteomic Tumor Analysis Consortium Data Coordinating Center.

REFERENCES

1. DeBerardinis RJ. Is cancer a disease of abnormal cellular metabolism? New angles on an old idea. Genet Med. 2008;10:767–777. [PMC free article] [PubMed]
2. Kroemer G, Pouyssegur J. Tumor cell metabolism: cancer's Achilles’ heel. Cancer Cell. 2008;13:472–482. [PubMed]
3. Vander Heiden MG. Targeting cancer metabolism: a therapeutic window opens. Nat Rev Drug Discov. 2011;10:671–684. [PubMed]
4. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science. 2009;324:1029–1033. [PMC free article] [PubMed]
5. Warburg O, Wind F, Negelein E. The metabolism of tumors in the body. J Gen Physiol. 1927;8:519–530. [PMC free article] [PubMed]
6. Mankoff DA, Eary JF, Link JM, Muzi M, Rajendran JG, Spence AM, Krohn KA. Tumor-specific positron emission tomography imaging in patients: [18F] fluorodeoxyglucose and beyond. Clin Cancer Res. 2007;13:3460–3469. [PubMed]
7. Schoder H, Gonen M. Screening for cancer with PET, PET/CT: potential and limitations. J Nucl Med. 2007;48:4S–18S. [PubMed]
8. Zaidi N, Lupien L, Kuemmerle NB, Kinlaw WB, Swinnen JV, Smans K. Lipogenesis and lipolysis: the pathways exploited by the cancer cells to acquire fatty acids. Prog Lipid Res. 2013;52:585–589. [PMC free article] [PubMed]
9. Fritz V, Fajas L. Metabolism and proliferation share common regulatory pathways in cancer cells. Oncogene. 2010;29:4369–4377. [PMC free article] [PubMed]
10. Menendez JA, Lupu R. Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nat Rev Cancer. 2007;7:763–777. [PubMed]
11. Zhang F, Du G. Dysregulated lipid metabolism in cancer. World J Biol Chem. 2012;3:167–174. [PMC free article] [PubMed]
12. Bhatt AP, Jacobs SR, Freemerman AJ, Makowski L, Rathmell JC, Dittmer DP, Damania B. Dysregulation of fatty acid synthesis and glycolysis in non-Hodgkin lymphoma. Proc Natl Acad Sci USA. 2012;109:11818–11823. [PubMed]
13. Kuhajda FP, Jenner K, Wood FD, Hennigar RA, Jacobs LB, Dick JD, Pasternack GR. Fatty acid synthesis: a potential selective target for antineoplastic therapy. Proc Natl Acad Sci USA. 1994;91:6379–6383. [PubMed]
14. Rashid A, Pizer ES, Moga M, Milgraum LZ, Zahurak M, Pasternack GR, Kuhajda FP, Hamilton SR. Elevated expression of fatty acid synthase and fatty acid synthetic activity in colorectal neoplasia. Am J Pathol. 1997;150:201–208. [PubMed]
15. Medes G, Thomas A, Weinhouse S. Metabolism of neoplastic tissue. IV. A study of lipid synthesis in neoplastic tissue slices in vitro. Cancer Res. 1953;13:27–29. [PubMed]
16. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90. [PubMed]
17. Wanders LK, East JE, Uitentuis SE, Leeflang MM, Dekker E. Diagnostic performance of narrowed spectrum endoscopy, autofluorescence imaging, and confocal laser endomicroscopy for optical diagnosis of colonic polyps: a meta-analysis. The Lancet Oncology. 2013;14:1337–1347. [PubMed]
18. Xu JF, Yang L, Jin P, Sheng JQ. Endoscopic Approach for Superficial Colorectal Neoplasms. Gastrointestinal tumors. 2016;3:69–80. [PMC free article] [PubMed]
19. Dunbar KB. Endomicroscopy in Barrett's esophagus. Gastrointest Endosc Clin N Am. 2013;23:565–579. [PubMed]
20. Kiesslich R, Burg J, Vieth M, Gnaendiger J, Enders M, Delaney P, Polglase A, McLaren W, Janell D, Thomas S, Nafe B, Galle PR, Neurath MF. Confocal laser endoscopy for diagnosing intraepithelial neoplasias and colorectal cancer in vivo. Gastroenterology. 2004;127:706–713. [PubMed]
21. Liu J, Zuo X, Li C, Yu T, Gu X, Zhou C, Li Z, Goetz M, Kiesslich R, Li Y. In vivo molecular imaging of epidermal growth factor receptor in patients with colorectal neoplasia using confocal laser endomicroscopy. Cancer Lett. 2013;330:200–207. [PubMed]
22. Foersch S, Kiesslich R, Waldner MJ, Delaney P, Galle PR, Neurath MF, Goetz M. Molecular imaging of VEGF in gastrointestinal cancer in vivo using confocal laser endomicroscopy. Gut. 2010;59:1046–1055. [PubMed]
23. Goetz M, Ziebart A, Foersch S, Vieth M, Waldner MJ, Delaney P, Galle PR, Neurath MF, Kiesslich R. In vivo molecular imaging of colorectal cancer with confocal endomicroscopy by targeting epidermal growth factor receptor. Gastroenterology. 2010;138:435–446. [PubMed]
24. Hsiung PL, Hardy J, Friedland S, Soetikno R, Du CB, Wu AP, Sahbaie P, Crawford JM, Lowe AW, Contag CH, Wang TD. Detection of colonic dysplasia in vivo using a targeted heptapeptide and confocal microendoscopy. Nat Med. 2008;14:454–458. [PMC free article] [PubMed]
25. Nie B, Park HM, Kazantzis M, Lin M, Henkin A, Ng S, Song SJ, Chen YL, Tran H, Lai RB, Her C, Maher JJ, Forman BM, et al. Specific bile acids inhibit hepatic fatty acid uptake in mice. Hepatology. 2012;56:1300–1310. [PMC free article] [PubMed]
26. Oikonomou E, Kothonidis K, Taoufik E, Probert E, Zografos G, Nasioulas G, Andera L, Pintzas A. Newly established tumourigenic primary human colon cancer cell lines are sensitive to TRAIL-induced apoptosis in vitro and in vivo. Br J Cancer. 2007;97:73–84. [PMC free article] [PubMed]
27. Thaker AI, Shaker A, Rao MS, Ciorba MA. Modeling colitis-associated cancer with azoxymethane (AOM) and dextran sulfate sodium (DSS) J Vis Exp. 2012. [PubMed]
28. Gheonea DI, Saftoiu A, Ciurea T, Popescu C, Georgescu CV, Malos A. Confocal laser endomicroscopy of the colon. J Gastrointestin Liver Dis. 2010;19:207–211. [PubMed]
29. Goetz M, Toermer T, Vieth M, Dunbar K, Hoffman A, Galle PR, Neurath MF, Delaney P, Kiesslich R. Simultaneous confocal laser endomicroscopy and chromoendoscopy with topical cresyl violet. Gastrointest Endosc. 2009;70:959–968. [PubMed]
30. Schlemper RJ, Riddell RH, Kato Y, Borchard F, Cooper HS, Dawsey SM, Dixon MF, Fenoglio-Preiser CM, Flejou JF, Geboes K, Hattori T, Hirota T, Itabashi M, et al. The Vienna classification of gastrointestinal epithelial neoplasia. Gut. 2000;47:251–255. [PMC free article] [PubMed]
31. Maxwell AE. Comparing the classification of subjects by two independent judges. Br J Psychiatry. 1970;116:651–655. [PubMed]
32. Brass E, Hanson E, O’Tierney-Ginn PF. Placental oleic acid uptake is lower in male offspring of obese women. Placenta. 2013;34:503–509. [PMC free article] [PubMed]
33. Kolahi K, Louey S, Varlamov O, Thornburg K. Real-Time Tracking of BODIPY-FA Long-Chain Fatty Acid in Human Term Placenta Reveals Unique Lipid Dynamics in Cytotrophoblast Cells. PLoS One. 2016;11:e0153522. [PMC free article] [PubMed]
34. Bionaz M, Thering BJ, Loor JJ. Fine metabolic regulation in ruminants via nutrient–gene interactions: saturated long-chain fatty acids increase expression of genes involved in lipid metabolism and immune response partly through PPAR-α activation. Br J Nutr. 2011;107:179–191. [PubMed]
35. Misawa M, Kudo SE, Wada Y, Nakamura H, Toyoshima N, Hayashi S, Mori Y, Kudo T, Hayashi T, Wakamura K, Miyachi H, Yamamura F, Hamatani S. Magnifying narrow-band imaging of surface patterns for diagnosing colorectal cancer. Oncol Rep. 2013;30:350–356. [PubMed]
36. Choi HJ, Lee BI, Choi H, Choi KY, Kim SW, Song JY, Ji JS, Kim BW. Diagnostic accuracy and interobserver agreement in predicting the submucosal invasion of colorectal tumors using gross findings, pit patterns, and microvasculatures. Clinical endoscopy. 2013;46:168–171. [PMC free article] [PubMed]
37. Sung HY, Cheung DY, Cho SH, Kim JI, Park SH, Han JY, Park GS, Kim JK, Chung IS. Polyps in the gastrointestinal tract: discrepancy between endoscopic forceps biopsies and resected specimens. Eur J Gastroenterol Hepatol. 2009;21:190–195. [PubMed]
38. Xie XJ, Li CQ, Zuo XL, Yu T, Gu XM, Li Z, Ji R, Wang Q, Li YQ. Differentiation of colonic polyps by confocal laser endomicroscopy. Endoscopy. 2011;43:87–93. [PubMed]
39. Coda S, Thillainayagam AV. State of the art in advanced endoscopic imaging for the detection and evaluation of dysplasia and early cancer of the gastrointestinal tract. Clin Exp Gastroenterol. 2014;7:133–150. [PMC free article] [PubMed]
40. Goetz M, Wang TD. Molecular imaging in gastrointestinal endoscopy. Gastroenterology. 2010;138:828–833. e821. [PMC free article] [PubMed]
41. Che L, Pilo MG, Cigliano A, Latte G, Simile MM, Ribback S, Dombrowski F, Evert M, Chen X, Calvisi DF. Oncogene dependent requirement of fatty acid synthase in hepatocellular carcinoma. Cell cycle. 2017;16:499–507. [PubMed]
42. Li L, Che L, Tharp KM, Park HM, Pilo MG, Cao D, Cigliano A, Latte G, Xu Z, Ribback S, Dombrowski F, Evert M, Gores GJ, et al. Differential requirement for de novo lipogenesis in cholangiocarcinoma and hepatocellular carcinoma of mice and humans. Hepatology. 2016;63:1900–1913. [PMC free article] [PubMed]
43. Ventura R, Mordec K, Waszczuk J, Wang Z, Lai J, Fridlib M, Buckley D, Kemble G, Heuer TS. Inhibition of de novo Palmitate Synthesis by Fatty Acid Synthase Induces Apoptosis in Tumor Cells by Remodeling Cell Membranes, Inhibiting Signaling Pathways, and Reprogramming Gene Expression. EBioMedicine. 2015;2:808–824. [PMC free article] [PubMed]
44. Svensson RU, Parker SJ, Eichner LJ, Kolar MJ, Wallace M, Brun SN, Lombardo PS, Van Nostrand JL, Hutchins A, Vera L, Gerken L, Greenwood J, Bhat S, et al. Inhibition of acetyl-CoA carboxylase suppresses fatty acid synthesis and tumor growth of non-small-cell lung cancer in preclinical models. Nature medicine. 2016;22:1108–1119. [PMC free article] [PubMed]
45. Rohrig F, Schulze A. The multifaceted roles of fatty acid synthesis in cancer. Nat Rev Cancer. 2016;16:732–749. [PubMed]
46. Currie E, Schulze A, Zechner R, Walther TC, Farese RV., Jr Cellular fatty acid metabolism and cancer. Cell metabolism. 2013;18:153–161. [PMC free article] [PubMed]

Articles from Oncotarget are provided here courtesy of Impact Journals, LLC